Paterna, Valencia, SPAIN and Maastricht, THE NETHERLANDS – 26 November 2025, Curapath, a leading innovator in the development and manufacturing of polymer and lipid-based drug delivery systems, and Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced they entered into a co-exclusive license agreement for the CliCr® bioconjugation platform. The platform offers a […]

Maastricht, The Netherlands – 11 September 2025 Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced it has entered into a non-exclusive license agreement with Sapreme Technologies. The agreement allows Sapreme Technologies to leverage the versatile and highly efficient CliCr® platform in the development of next-generation therapeutics based on their endosomal escape technology. […]

20230117 Lonza collaborates with Cristal Therapeutics “CliCr® is a powerful metal-free click chemistry technology for the life science industry which offers shorter reaction times and greater yields and hence attractive CoG than comparative reagents on the market. Our collaboration with Lonza will help to extend the impact of this innovative technology for use in straightforward […]

Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development CliCr® can be partnered or licensed as a stand-alone technology Cristal is actively seeking partners for CliCr® for a variety of applications Maastricht, The Netherlands, 29 September 2020 – Cristal Therapeutics, […]